Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Update

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the target of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 159,600 shares, a decrease of 96.2% from the February 28th total of 4,160,000 shares. Approximately 14.9% of the shares of the company are sold short. Based on an average trading volume of 936,100 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On Hepion Pharmaceuticals

An institutional investor recently bought a new position in Hepion Pharmaceuticals stock. Anson Funds Management LP purchased a new stake in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned 3.33% of Hepion Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 17.24% of the company’s stock.

Hepion Pharmaceuticals Stock Down 3.9 %

Shares of NASDAQ HEPA traded down $0.03 during trading on Wednesday, reaching $0.69. 2,502,279 shares of the company traded hands, compared to its average volume of 255,378. The firm has a 50 day simple moving average of $7.46 and a 200-day simple moving average of $22.90. Hepion Pharmaceuticals has a 52-week low of $0.55 and a 52-week high of $145.00. The stock has a market capitalization of $95,215.00, a PE ratio of -0.16 and a beta of 1.62.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.